Skip to main content
SpringerLink
Log in

Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression

  • Leading Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

This paper reviews the discovery and history of the use of irreversible monoamine oxidase (MAO) inhibitors (MAOIs) such as phenelzine, tranylcypromine and isocarboxazid, as well as the second generation selective and reversible MAOIs such as the MAO-A inhibitor, moclobemide and the MAO-B inhibitor, selegiline. Data for review were identified from a literature search of OvidSP Medline and PsycInfo performed in July 2012, using the subject terms and keywords of ‘monoamine oxidase inhibitors’, ‘major depression’, ‘depressive disorder’ and ‘depression (emotion)’. The search was limited to papers published in the English language and from 2007 onward only.

Irreversible MAOIs have the potential to treat the most challenging mood disorder patients including those with treatment-resistant depression, atypical depression and bipolar depression. Unfortunately, the use of irreversible MAOIs has been declining sharply due to lack of marketing and the excessive fears of clinicians. Moreover, few clinicians now have any experience, let alone comfort, in prescribing this class of antidepressants. The newer MAOIs are available as another option for the treatment of major depression but have not replaced the irreversible MAOIs for the specific sub-types of depression for which they are now recommended in most consensus guidelines and treatment algorithms.

The pharmacology, drug interactions and dietary recommendations associated with the use of MAOIs are reviewed. With the appropriate dietary restrictions and attention to potential drug interactions with serotonin and noradrenaline agents this class of drugs can be used effectively and safely. The MAOIs still represent an important element in our therapeutic armamentarium. Despite recommendations by opinion leaders and consensus guidelines for the use of MAOIs in specific sub-types of depression, the prescription rate of MAOIs is far less than expected and is decreasing. The “bad reputation” and the lack of industry support for this class of agents (especially the irreversible MAOIs) must be overcome in order to continue to provide a potentially useful treatment for a very vulnerable yet substantial sub-population of mood disorder patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Papakosta GI, Bech P, Fava M. Pharmacological treatment of major depressive disorder: a review, in depressive disorders. In: Herrmann H, Maj M, Sartorius N, editors. New York: Wiley; 2009. p. 47–74.

  2. Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des. 2009;15(14):1563–86.

    Article  PubMed  CAS  Google Scholar 

  3. Shih JC, Chen K. Regulation of MAO-A and MAO-B gene expression. Curr Med Chem. 2004;11(15):1995–2005.

    Article  PubMed  CAS  Google Scholar 

  4. Kalgutkar AS, Dalvie DK, Castagnoli N Jr, et al. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol. 2001;14(9):1139–62.

    Article  PubMed  CAS  Google Scholar 

  5. Andres N, Lizcano JM, Rodriguez MJ, et al. Tissue activity and cellular localization of human semicarbazide-sensitive amine oxidase. J Histochem Cytochem. 2001;49(2):209–17.

    Article  PubMed  CAS  Google Scholar 

  6. Billett EE. Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology. 2004;25(1–2):139–48.

    Article  PubMed  CAS  Google Scholar 

  7. Lewinsohn R, Glover V, Sandler M. Beta-phenylethylamine and benzylamine as substrates for human monoamine oxidase A: a source of some anomalies? Biochem Pharmacol. 1980;29(5):777–81.

    Article  PubMed  CAS  Google Scholar 

  8. Campbell IC, Marangos PJ, Parma A, et al. Localization of monoamine oxidases A and B in primate brains relative to neuron-specific and non-neuronal enolases. Neurochem Res. 1982;7(6):657–66.

    Article  PubMed  CAS  Google Scholar 

  9. Finberg JP, Gillman K. Selective inhibitors of monoamine oxidase type B and the “cheese effect”. Int Rev Neurobiol. 2011;100:169–90.

    Article  PubMed  CAS  Google Scholar 

  10. Bieck PR, Firkusny L, Schick C, et al. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clin Pharmacol Ther. 1989;45(3):260–9.

    Article  PubMed  CAS  Google Scholar 

  11. Tiller JW, Maguire KP, Davies BM. Tyramine pressor response with moclobemide—a reversible monoamine oxidase inhibitor. Psychiatry Res. 1987;22(3):213–20.

    Article  PubMed  CAS  Google Scholar 

  12. Sunderland T, Mueller EA, Cohen RM, et al. Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology (Berl). 1985;86(4):432–7.

    Article  CAS  Google Scholar 

  13. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95(4):434–41.

    Article  PubMed  CAS  Google Scholar 

  14. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med. 2010;77(12):859–82.

    Article  PubMed  Google Scholar 

  15. Lemberger L, Bergstrom RF, Wolen RL, et al. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry. 1985;46(3 Pt 2):14–9.

    PubMed  CAS  Google Scholar 

  16. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. Lancet. 1991;337(8735):246.

    Article  PubMed  CAS  Google Scholar 

  17. Boakes AJ, Laurence DR, Teoh PC, et al. Interactions between sympathomimetic amines and antidepressant agents in man. Br Med J. 1973;1(5849):311–5.

    Article  PubMed  CAS  Google Scholar 

  18. Gillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol. 2011;31(1):66–74.

    Article  PubMed  CAS  Google Scholar 

  19. Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet. 1963;2(7313):849–50.

    Article  PubMed  CAS  Google Scholar 

  20. Sullivan EA, Shulman KI. Diet and monoamine oxidase inhibitors: a re-examination. Can J Psychiatry. 1984;29(8):707–11.

    PubMed  CAS  Google Scholar 

  21. Shulman KI, Walker SE, MacKenzie S, et al. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989;9(6):397–402.

    Article  PubMed  CAS  Google Scholar 

  22. Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry. 2007;68(Suppl 8):35–41.

    PubMed  CAS  Google Scholar 

  23. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12(3):185–219.

    Article  PubMed  CAS  Google Scholar 

  24. Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry. 1989;46(9):783–6.

    Article  PubMed  CAS  Google Scholar 

  25. Robinson DS, Nies A, Davis JN, et al. Ageing, monoamines, and monoamine-oxidase levels. Lancet. 1972;1(7745):290–1.

    Article  PubMed  CAS  Google Scholar 

  26. Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006;63(11):1209–16.

    Article  PubMed  CAS  Google Scholar 

  27. Liebowitz MR. Depression with anxiety and atypical depression. J Clin Psychiatry. 1993;54(Suppl):10–4 Discussion 15.

    PubMed  Google Scholar 

  28. Parker G, Roy K, Mitchell P, et al. Atypical depression: a reappraisal. Am J Psychiatry. 2002;159(9):1470–9.

    Article  PubMed  Google Scholar 

  29. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl. 1993;21:30–4.

    PubMed  Google Scholar 

  30. Henkel V, Mergl R, Allgaier AK, et al. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res. 2006;141(1):89–101.

    Article  PubMed  Google Scholar 

  31. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry. 1993;150(1):118–23.

    PubMed  CAS  Google Scholar 

  32. Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors. J Clin Psychiatry. 1992;53(1):5–11.

    PubMed  CAS  Google Scholar 

  33. Fekadu A, Rane LJ, Wooderson SC, et al. Prediction of longer-term outcome of treatment-resistant depression in tertiary care. Br J Psychiatry. 2012;201(5):369–75.

    Article  PubMed  Google Scholar 

  34. Hamani C, Temel Y. Deep brain stimulation for psychiatric disease: contributions and validity of animal models. Sci Transl Med. 2012;4(142):142rv8.

    Article  PubMed  Google Scholar 

  35. American Psychiatric Association. Practice guideline for the treatment of patients with major depression disorder, vol 167; (2010).

  36. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009;117(Suppl 1):S26–43.

    Article  PubMed  Google Scholar 

  37. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66(7):870–86.

    Article  PubMed  Google Scholar 

  38. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003;17(2):149–73 discussion 147.

    Article  PubMed  CAS  Google Scholar 

  39. Spijker J, Nolen WA. An algorithm for the pharmacological treatment of depression. Acta Psychiatr Scand. 2010;121(3):180–9.

    Article  PubMed  CAS  Google Scholar 

  40. Nolen WA, Kupka RW, Hellemann G, et al. Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand. 2007;115(5):360–5.

    Article  PubMed  CAS  Google Scholar 

  41. Stewart JW. Treating depression with atypical features. J Clin Psychiatry. 2007;68(Suppl 3):25–9.

    PubMed  Google Scholar 

  42. Preskorn SH. Results of the STAR*D study: implications for clinicians and drug developers. J Psychiatr Pract. 2009;15(1):45–9.

    Article  PubMed  Google Scholar 

  43. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1531–41 quiz 1666.

    Article  PubMed  Google Scholar 

  44. Nolen WA, van den Broek WW, Birkenhager TK. Treatment with low doses of tranylcypromine resulted in a disappointing remission rate. Am J Psychiatry. 2007;164(3):524 author reply 524.

    Article  PubMed  Google Scholar 

  45. Shulman KI, Fischer HD, Herrmann N, et al. Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults. J Clin Psychiatry. 2009;70(12):1681–6.

    Article  PubMed  Google Scholar 

  46. Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology. 2004;25(1–2):215–21.

    Article  PubMed  CAS  Google Scholar 

  47. Goodnick PJ. Seligiline transdermal system in depression. Expert Opin Pharmacother. 2007;8(1):59–64.

    Article  PubMed  CAS  Google Scholar 

  48. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343–96.

    Article  PubMed  CAS  Google Scholar 

  49. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry. 2002;3(1):5–43.

    Article  PubMed  Google Scholar 

  50. National Institute for Health and Clinical Excellence. Depression in adults: the treatment and management of depression in adults. 2009. http://www.nice.org.uk/nicemedia/live/12329/45888/45888.pdf.

  51. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20(3):226–47.

    Article  PubMed  CAS  Google Scholar 

  52. Delini-Stula A, Mikkelsen H, Angst J. Therapeutic efficacy of antidepressants in agitated anxious depression—a meta-analysis of moclobemide studies. J Affect Disord. 1995;35(1–2):21–30.

    Article  PubMed  CAS  Google Scholar 

  53. Lonnqvist J, Sihvo S, Syvalahti E, et al. Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Disord. 1994;32(3):169–77.

    Article  PubMed  CAS  Google Scholar 

  54. Sogaard J, Lane R, Latimer P, et al. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol. 1999;13(4):406–14.

    Article  PubMed  CAS  Google Scholar 

  55. Versiani M, Amrein R, Stabl M. Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. Int Clin Psychopharmacol. 1997;12(4):183–93.

    Article  PubMed  CAS  Google Scholar 

  56. Nair NP, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo. J Affect Disord. 1995;33(1):1–9.

    Article  PubMed  CAS  Google Scholar 

  57. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159(11):1869–75.

    Article  PubMed  Google Scholar 

  58. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64(2):208–14.

    Article  PubMed  CAS  Google Scholar 

  59. Feiger AD, Rickels K, Rynn MA, et al. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006;67(9):1354–61.

    Article  PubMed  CAS  Google Scholar 

  60. Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol. 2006;26(6):579–86.

    Article  PubMed  CAS  Google Scholar 

  61. Fawcett J. Why aren’t MAOIs used more often? J Clin Psychiatry. 2009;70(1):139–40.

    Article  PubMed  Google Scholar 

  62. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008;13(10):855–70.

    PubMed  Google Scholar 

  63. O’Brien V. The monoamine oxidase inhibitor: relics reconsidered. Psychiatr Ann. 2011;41(3):176–83.

    Google Scholar 

  64. Goldberg JF, Thase ME. Monoamine oxidase inhibitors revisited: what you should know. J Clin Psychiatry. 2013;74(2):189–91.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Dr. Shulman is supported in part by the Lewar Chair in Geriatric Psychiatry. Dr. Shulman, Dr. Herrmann and Dr. Walker have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Professor, Department of Psychiatry, Faculty of Medicine, University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada

    Kenneth I. Shulman & Nathan Herrmann

  2. Associate Professor, Faculty of Pharmacy, University of Toronto, Director of Pharmacy and Division of Clinical Pharmacology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada

    Scott E. Walker

Authors
  1. Kenneth I. Shulman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathan Herrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Scott E. Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth I. Shulman.

Appendix

Appendix

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shulman, K.I., Herrmann, N. & Walker, S.E. Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression. CNS Drugs 27, 789–797 (2013). https://doi.org/10.1007/s40263-013-0097-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-013-0097-3

Keywords

Search

Navigation